INNOVO by Atlantic Therapeutics is a technology company.
INNOVO by Atlantic Therapeutics has raised $48.0M across 2 funding rounds.
INNOVO by Atlantic Therapeutics has raised $48.0M in total across 2 funding rounds.
INNOVO by Atlantic Therapeutics has raised $48.0M in total across 2 funding rounds.
INNOVO by Atlantic Therapeutics's investors include Atlantic Bridge, Borski Fund, Earlybird Venture Capital, Seroba Life Sciences.
INNOVO by Atlantic Therapeutics is a medical device developed by Atlantic Therapeutics, a medtech company specializing in non-invasive pelvic floor strengthening solutions for women's health, particularly stress urinary incontinence (SUI).[1][2][3] The core product, INNOVO shorts, deliver neuromuscular electrical stimulation (NMES) via wearable technology, targeting women worldwide who suffer from SUI—a condition affecting 1 in 3 women—by strengthening pelvic floor muscles in 30-minute home sessions, with clinical trials showing 87% of users dry or nearly dry after 12 weeks.[1][4] Atlantic Therapeutics raised $104M before its acquisition by Caldera Medical in September 2023, which expanded INNOVO's global reach while maintaining its Irish innovation hub.[1][3]
The company serves healthcare providers and direct-to-consumer patients, solving the unmet need for non-invasive SUI treatment amid growing demand for femtech solutions, backed by FDA clearance in 2018 as the first transcutaneous electrical stimulator for this use.[1][4][5] Post-acquisition, INNOVO integrates into Caldera Medical's women's health portfolio, driving growth in a market dominated by players like Johnson & Johnson.[2][3]
Atlantic Therapeutics spun out in 2017 from Bio-Medical Research (BMR) in Galway, Ireland, to commercialize INNOVO technology originally developed as the Vital Compact device, which had gained regulatory approval and traction in Europe.[1][2] The idea emerged from BMR's innovation in NMES for pelvic floor rehabilitation, leveraging a strong patent portfolio and freedom-to-operate analyses to attract investors for U.S. expansion.[2] A pivotal moment came in November 2018 with FDA De Novo clearance, making INNOVO the first non-invasive, wearable stimulator for SUI, supported by trials on over 600 subjects.[1][2][4][5]
Early funding milestones included Series A and B rounds, with investors like Seroba Life Sciences citing the large unmet need, non-invasive design, and IP strength; by 2021, it secured additional backers for femtech growth.[2][6] Leadership, including CEO Susan Trent, emphasized clinical robustness, leading to the 2023 acquisition by Caldera Medical, which preserved the Galway team and accelerated worldwide scaling.[3]
Atlantic Therapeutics rides the femtech wave, addressing a $10B+ SUI market with non-invasive alternatives to surgical interventions from giants like Boston Scientific.[2] Timing aligns with rising awareness of women's pelvic health post-pregnancy/childbirth, amplified by remote health tech post-COVID and FDA's support for digital therapeutics.[1][4] Market forces favor INNOVO: aging populations, stigma reduction around incontinence, and investor interest in evidence-based medtech, as seen in its $104M funding and acquisition.[1][3][6]
It influences the ecosystem by pioneering NMES wearables, inspiring connected health devices for pelvic/sexual dysfunctions, and validating spin-outs from research hubs like Galway—boosting Ireland's medtech scene while integrating into Caldera’s prolapse/fibroid portfolio for holistic women's care.[2][3]
Under Caldera Medical, INNOVO is poised for explosive global expansion, targeting U.S./Asia growth with its clinical edge and OTC appeal amid femtech's projected doubling by 2030. Trends like AI-enhanced apps, expanded indications (e.g., sexual health), and telehealth partnerships will propel it, potentially capturing first-mover share in non-invasive SUI. Its evolution from Irish spin-out to acquired leader underscores medtech's power to transform daily burdens for millions of women into leak-free lives.[1][2][3]
INNOVO by Atlantic Therapeutics has raised $48.0M across 2 funding rounds. Most recently, it raised $32.0M Series B in January 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2019 | $32.0M Series B | Atlantic Bridge, Borski Fund, Earlybird Venture Capital, Seroba Life Sciences | |
| Feb 1, 2017 | $16.0M Series A | Earlybird Venture Capital, Seroba Life Sciences |